Cystic Fibrosis drugs to cost €400 million over ten years

Cystic Fibrosis drugs to cost €400 million over ten years

The HSE and the drug’s maker Vertex have reached a deal in principle on providing the drugs Orkambi and Kalydeco to CF patients

The deal to provide life-changing drugs to cystic fibrosis sufferers will cost the state close to €400 million over ten years.

Please Subscribe or Log in to continue reading

Subscribe Login

Independent journalism every day

With digital access you can read The Business Post whenever, wherever, and however you want.

  • Unlimited access to all sections of The Business Post on desktop, tablet and mobile.
  • Breaking news, comment and analysis from the best Business Post writers seven days a week.
  • Live blogs of major news events
  • Videos and podcasts from some of the industry's most respected journalists such as Tom Lyons, Susan Mitchell and Ian Guider
  • Access to The Business Post's extensive archive​

Related Articles

More from The Business Post